




# CentoMetabolic™



## CentoMetabolic™ – A one test solution for rare metabolic disorders

We are committed to providing solutions to help end the diagnostic odyssey of patients suffering from rare diseases. We have developed CentoMetabolic™, a panel that integrates genetic and biochemical testing to diagnose a wide range of rare metabolic disorders. Our panel includes a comprehensive range of genes combined with biochemical testing — including enzyme assays and a selection of proprietary biomarkers. When variants relevant to your patient are detected, we will automatically complement the genetic testing with biomarker and/or enzyme testing and include the results in your medical report.

CentoMetabolic™ gives the confidence of a thorough evaluation for a potential metabolic diagnosis while at the same time providing an opportunity to validate the consequences of the identified genetic variant.\*

\*when applicable

## Who should consider CentoMetabolic™?

Physicians providing treatment for patients matching any of the following criteria:

- Suspected metabolic disorder
- Complex, overlapping symptoms with broad differential diagnosis
- Metabolic crisis
- Abnormal newborn screening results
- Admission to a neonatal intensive care unit
- Symptoms related to neurological conditions of unknown etiology

## What genes and disorders are targeted by CentoMetabolic™?

CentoMetabolic™ includes 166 genes and targets more than 150 metabolic disorders. The content and design of the panel is based on our continuously enhanced medical expertise and knowledge in rare metabolic diseases.

The following table shows the distribution of genes and targeted metabolic disorders depending on 11 different disease categories.

TYPES OF METABOLIC DISORDERS COVERED	TARGETED DISORDERS	NUMBER OF GENES*
Disorders of Carbohydrate Metabolism	31	33
Disorders of Cholesterol and Lipoprotein Metabolism	29	31
Disorders of Amino and Organic Acid Metabolism	19	24
Disorders of Glycolipid and Glycoprotein Metabolism	18	17
Transmembrane Protein Defects	17	17
Peroxisomal Disorders	17	16
Porphyrias and Bilirubinemia	12	13
Disorders of Hormone Biogenesis or Function	6	6
Disorders of Nucleotide Metabolism	4	4
Disorders of Metal Metabolism and Transport	3	6
Disorders of Phosphate Metabolism	3	3

\*Due to overlapping phenotypes, particular genes are listed in more than one category as they are associated with more than one disorder

### CONTACT AND CUSTOMER SERVICE

Phone: +49 (0)381 80 113-416    Email: [customer.support@centogene.com](mailto:customer.support@centogene.com)  
 Fax: +49 (0)381 80 113-401    [www.centogene.com](http://www.centogene.com)


**CLIA #99D2049715**  
 Following GLP and  
 GMP guidelines.





## CENTOGENE's biomarkers and enzyme testing

Biomarkers serve as measurable indicators of normal biological or pathological processes. They are typically directly linked to genetic variants in specific genes and can predict, diagnose, monitor and assess the severity of a disease. Measuring the cellular activity of an enzyme can also be used as a tool for the diagnosis and monitoring of a disease. Our multiomic and big data based approaches allow us to continuously discover new highly specific biomarkers. Any new biomarker will be included in this panel and represents an opportunity to advance our understanding of rare metabolic diseases as well as to develop better tailored therapies for patients.



## CentoMetabolic™ - Key features

- Bidirectional next-generation sequencing of target regions of all 166 genes in the panel, including coding regions and +/- 10 bp exon/intron boundaries
- All relevant deep intronic variants described in CentoMD® and HGMD® are included
- Coverage: ≥99.5% of targeted regions covered at ≥ 20x
- Low quality single nucleotide variants (SNVs) and all relevant deletion/insertion variants are confirmed by Sanger sequencing prior to reporting
- Fast and precise diagnostic with a TAT of 6–10 business days
- Specificity of >99.9% for all reported variants
- Our test combines genetic and biochemical testing for the widest range of rare metabolic diseases
- Complementary biochemical testing by proprietary biomarkers and enzyme-activity assays when applicable
- Required Material: ≥ 1 filter card

### GENES INCLUDED

ABCA1, ABCC2, ABCD1, ABCD4, ADA, AGA, AGL, AGPS, ALAD, ALAS2, ALDOA, ALDOB, ALPL, APOA2, APOA5, APOB, APOC2, APOE, ARG1, ARSA, ARSB, ASAH1, ASL, ASS1, ATP7A, ATP7B, BCKDHA, BCKDHB, CBS, CETP, CLN3, CLN5, CLN6, CLN8, CPOX, CPS1, CTNS, CTSA, CTSD, CTSK, CYP11B1, CYP17A1, CYP19A1, CYP21A2, DBT, DHCR7, ENO3, ENPP1, EPHX2, FECH, FGF23, FUCA1, G6PC, G6PD, GAA, GALC, GALE, GALK1, GALNS, GALT, GBA, GBE1, GHR, GK, GLA, GLB1, GM2A, GNPAT, GNPTAB, GNPTG, GNS, GUSB, GYG1, GYS2, HCFC1, HEXA, HEXB, HFE, HFE2, HGD, HGSNAT, HMBS, HPRT1, HSD3B2, HYAL1, IDS, IDUA, ITIH4, KHK, LAMP2, LCAT, LDHA, LDLR, LIPA, LIPI, LMBRD1, LPA, LPL, MAN2B1, MANBA, MCOLN1, MFSD8, MMACHC, MMADHC, NAGA, NAGLU, NAGS, NEU1, NPC1, NPC2, OTC, PAH, PEX1, PEX10, PEX12, PEX13, PEX14, PEX16, PEX19, PEX2, PEX26, PEX3, PEX5, PEX6, PEX7, PFKM, PGAM2, PGK1, PGM1, PHKA1, PHKA2, PHKB, PHKG2, PKLR, POR, PPOX, PPP1R17, PPT1, PRKAG2, PYGL, PYGM, RBCK1, SGSH, SLC17A5, SLC25A13, SLC25A15, SLC25A36, SLC2A1, SLC2A2, SLC2A3, SLC3A1, SLC3A2, SLC40A1, SLC6A19, SLC7A7, SLC7A9, SLCO1B1, SLCO1B3, SMPD1, SUMF1, TFR2, TPP1, UGT1A1, UMPS, UROD, UROS